Muon Spin Relaxation Studies of Magnetic-Field-Induced Effects in High-TcT_{c} Superconductors

Muon spin relaxation ($\mu$SR) measurements in high transverse magnetic fields ($\parallel \hat c$) revealed strong field-induced quasi-static magnetism in the underdoped and Eu doped (La,Sr)$_{2}$CuO$_{4}$ and La$_{1.875}$Ba$_{0.125}$CuO$_{4}$, existing well above $T_{c}$ and $T_{N}$. The susceptibility-counterpart of Cu spin polarization, derived from the muon spin relaxation rate, exhibits a divergent behavior towards $T \sim 25$ K. No field-induced magnetism was detected in overdoped La$_{1.81}$Sr$_{0.19}$CuO$_{4}$, optimally doped Bi2212, and Zn-doped YBa$_{2}$Cu$_{3}$O$_{7}$.Comment: 4 pages, 4 color figure

Site-Dilution in quasi one-dimensional antiferromagnet Sr2(Cu1-xPdx)O3: reduction of Neel Temperature and spatial distribution of ordered moment sizes

We investigate the Neel temperature of Sr2CuO3 as a function of the site dilution at the Cu (S=1/2) sites with Pd (S=0), utilizing the muon spin relaxation (muSR) technique. The Neel temperature, which is Tn=5.4K for the undoped system, becomes significantly reduced for less than one percent of doping Pd, giving a support for the previous proposal for the good one-dimensionality. The Pd concentration dependence of the Neel temperature is compared with a recent theoretical study (S. Eggert, I. Affleck and M.D.P. Horton, Phys. Rev. Lett. 89, 47202 (2002)) of weakly coupled one-dimensional antiferromagnetic chains of S=1/2 spins, and a quantitative agreement is found. The inhomogeneity of the ordered moment sizes is characterized by the muSR time spectra. We propose a model that the ordered moment size recovers away from the dopant S=0 sites with a recovery length of \xi = 150-200 sites. The origin of the finite recovery length \xi for the gapless S=1/2 antiferromagnetic chain is compared to the estimate based on the effective staggered magnetic field from the neighboring chains.Comment: 10 pages, 9 figures, submitted to PR

Muon Spin Relaxation and Susceptibility Studies of Pure and Doped Spin 1/2 Kagom\'{e}-like system (Cux_xZn1−x_{1-x})3_{3}V2_{2}O7_7(OH)2_{2} 2H2_2O

Muon spin relaxation ($\mu$SR) and magnetic susceptibility measurements have been performed on the pure and diluted spin 1/2 kagom\'{e} system (Cu$_x$Zn$_{1-x}$)$_{3}$V$_{2}$O$_7$(OH)$_{2}$ 2H$_2$O. In the pure $x=1$ system we found a slowing down of Cu spin fluctuations with decreasing temperature towards $T \sim 1$ K, followed by slow and nearly temperature-independent spin fluctuations persisting down to $T$ = 50 mK, indicative of quantum fluctuations. No indication of static spin freezing was detected in either of the pure ($x$=1.0) or diluted samples. The observed magnitude of fluctuating fields indicates that the slow spin fluctuations represent an intrinsic property of kagom\'e network rather than impurity spins.Comment: 4 pges, 4 color figures, Phys. Rev. Lett. in pres

Reconciling Semiclassical and Bohmian Mechanics: III. Scattering states for continuous potentials

In a previous paper [J. Chem. Phys. 121 4501 (2004)] a unique bipolar decomposition, Psi = Psi1 + Psi2 was presented for stationary bound states Psi of the one-dimensional Schroedinger equation, such that the components Psi1 and Psi2 approach their semiclassical WKB analogs in the large action limit. The corresponding bipolar quantum trajectories, as defined in the usual Bohmian mechanical formulation, are classical-like and well-behaved, even when Psi has many nodes, or is wildly oscillatory. A modification for discontinuous potential stationary stattering states was presented in a second paper [J. Chem. Phys. 124 034115 (2006)], whose generalization for continuous potentials is given here. The result is an exact quantum scattering methodology using classical trajectories. For additional convenience in handling the tunneling case, a constant velocity trajectory version is also developed.Comment: 16 pages and 14 figure

Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases:A nationwide comparative study

Objectives: In the Netherlands, limited variability exists in performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin.Methods: This was a comparative, population-based cohort study of all Dutch patients diagnosed with synchronous colorectal PM who underwent CRS-HIPEC between 2014 and 2017. They were retrieved from the Netherlands Cancer Registry. Main outcome was overall survival (OS). The effect of the intraperitoneal drug on OS was investigated using multivariable Cox regression analysis.Results: In total, 297 patients treated between 2014 and 2017 were included. Among them, 177 (59.6%) received MMC and 120 (40.4%) received oxaliplatin. Only primary tumor location was different between the two groups: more left-sided colon in the Oxaliplatin group (47.5% vs. 33.3%, respectively, p=0.048). The 1-, 2- and 3-year OS were 84.6% vs. 85.8%, 61.6% vs. 63.9% and 44.7% vs. 53.5% in patients treated with MMC and oxaliplatin, respectively. Median OS was 30.7 months in the MMC group vs. 46.6 months in the oxaliplatin group (p=0.181). In multivariable analysis, no influence of intraperitoneal drug on survival was observed (adjusted HR 0.77 [0.53-1.13]).Conclusions: Long-term survival between patients treated with either MMC or oxaliplatin during CRS-HIPEC was not significantly different. (C) 2020 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.</p

Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development

Market access and pricing of pharmaceuticals are increasingly contingent on the ability to demonstrate comparative effectiveness and cost-effectiveness. As such, it is widely recognized that predictions of the economic potential of drug candidates in development could inform decisions across the product life cycle. This may be challenging when safety and efficacy profiles in terms of the relevant clinical outcomes are unknown or highly uncertain early in product development. Linking pharmacometrics and pharmacoeconomics, such that outputs from pharmacometric models serve as inputs to pharmacoeconomic models, may provide a framework for extrapolating from early-phase studies to predict economic outcomes and characterize decision uncertainty. This article reviews the published studies that have implemented this methodology and used simulation to inform drug development decisions and/or to optimize the use of drug treatments. Some of the key practical issues involved in linking pharmacometrics and pharmacoeconomics, including the choice of final outcome measures, methods of incorporating evidence on comparator treatments, approaches to handling multiple intermediate end points, approaches to quantifying uncertainty, and issues of model validation are also discussed. Finally, we have considered the potential barriers that may have limited the adoption of this methodology and suggest that closer alignment between the disciplines of clinical pharmacology, pharmacometrics, and pharmacoeconomics, may help to realize the potential benefits associated with linked pharmacometric-pharmacoeconomic modeling and simulation

Selective accumulation of ALA-induced PpIX and photodynamic effect in chemically induced hepatocellular carcinoma

浜松医科大学学位論文　医博論第397号(平成１７年３月１０日

Ischemic Preconditioning in the Animal Kidney, a Systematic Review and Meta-Analysis

Ischemic preconditioning (IPC) is a potent renoprotective strategy which has not yet been translated successfully into clinical practice, in spite of promising results in animal studies. We performed a unique systematic review and meta-analysis of animal studies to identify factors modifying IPC efficacy in renal ischemia/reperfusion injury (IRI), in order to enhance the design of future (clinical) studies. An electronic literature search for animal studies on IPC in renal IRI yielded fifty-eight studies which met our inclusion criteria. We extracted data for serum creatinine, blood urea nitrogen and histological renal damage, as well as study quality indicators. Meta-analysis showed that IPC reduces serum creatinine (SMD 1.54 [95%CI 1.16, 1.93]), blood urea nitrogen (SMD 1.42 [95% CI 0.97, 1.87]) and histological renal damage (SMD 1.12 [95% CI 0.89, 1.35]) after IRI as compared to controls. Factors influencing IPC efficacy were the window of protection (<24 h = early vs. ≥24 h = late) and animal species (rat vs. mouse). No difference in efficacy between local and remote IPC was observed. In conclusion, our findings show that IPC effectively reduces renal damage after IRI, with higher efficacy in the late window of protection. However, there is a large gap in study data concerning the optimal window of protection, and IPC efficacy may differ per animal species. Moreover, current clinical trials on RIPC may not be optimally designed, and our findings identify a need for further standardization of animal experiments

Genetic Influences on Incidence and Case-Fatality of Infectious Disease

BACKGROUND: Family, twin and adoption studies suggest that genetic susceptibility contributes to familial aggregation of infectious diseases or to death from infections. We estimated genetic and shared environmental influences separately on the risk of acquiring an infection (incidence) and on dying from it (case fatality). METHODS: Genetic influences were estimated by the association between rates of hospitalization for infections and between case-fatality rates of adoptees and their biological full- and half- siblings. Familial environmental influences were investigated in adoptees and their adoptive siblings. Among 14,425 non-familial adoptions, granted in Denmark during the period 1924-47, we selected 1,603 adoptees, who had been hospitalized for infections and/or died with infection between 1977 and 1993. Their siblings were considered predisposed to infection, and compared with non-predisposed siblings of randomly selected 1,348 adoptees alive in 1993 and not hospitalized for infections in the observation period. The risk ratios presented were based on a Cox regression model. RESULTS: Among 9971 identified siblings, 2829 had been hospitalised for infections. The risk of infectious disease was increased among predisposed compared with non-predisposed in both biological (1.18; 95% confidence limits 1.03-1.36) and adoptive siblings (1.23; 0.98-1.53). The risk of a fatal outcome of the infections was strongly increased (9.36; 2.94-29.8) in biological full siblings, but such associations were not observed for the biological half siblings or for the adoptive siblings. CONCLUSION: Risk of getting infections appears to be weakly influenced by both genetically determined susceptibility to infection and by family environment, whereas there appears to be a strong non-additive genetic influence on risk of fatal outcome